What is Raymond James’ Forecast for PROF FY2028 Earnings?

Profound Medical Corp. (NASDAQ:PROF) – Investment analysts at Raymond James issued their FY2028 earnings per share estimates for Profound Medical in a research note issued on Thursday, November 7th. Raymond James analyst R. Sarugaser anticipates that the company will post earnings per share of $2.96 for the year. The consensus estimate for Profound Medical’s current full-year earnings is ($1.10) per share.

Profound Medical (NASDAQ:PROF) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, meeting analysts’ consensus estimates of ($0.28). The business had revenue of $2.23 million during the quarter, compared to analysts’ expectations of $2.50 million. Profound Medical had a negative return on equity of 80.99% and a negative net margin of 349.41%. During the same period in the previous year, the business earned ($0.35) earnings per share.

A number of other analysts have also issued reports on PROF. Stifel Nicolaus raised Profound Medical from a “hold” rating to a “buy” rating and lifted their price target for the stock from $9.00 to $12.00 in a research note on Tuesday, July 16th. Lake Street Capital started coverage on Profound Medical in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $16.50 price target on the stock.

Profound Medical Stock Down 2.3 %

Profound Medical stock opened at $8.75 on Monday. The stock has a market capitalization of $215.79 million, a PE ratio of -6.53 and a beta of 0.83. Profound Medical has a 12 month low of $7.11 and a 12 month high of $11.69. The business has a 50 day simple moving average of $7.82 and a 200-day simple moving average of $8.45. The company has a debt-to-equity ratio of 0.10, a current ratio of 8.61 and a quick ratio of 7.42.

Hedge Funds Weigh In On Profound Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PROF. Gagnon Advisors LLC boosted its stake in Profound Medical by 10.0% during the first quarter. Gagnon Advisors LLC now owns 747,226 shares of the company’s stock worth $6,374,000 after buying an additional 67,930 shares during the last quarter. Thompson Davis & CO. Inc. lifted its stake in shares of Profound Medical by 9.0% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 74,800 shares of the company’s stock valued at $628,000 after purchasing an additional 6,150 shares during the last quarter. Raymond James Trust N.A. acquired a new position in shares of Profound Medical in the 2nd quarter valued at $88,000. Royce & Associates LP lifted its stake in shares of Profound Medical by 0.6% in the 3rd quarter. Royce & Associates LP now owns 569,298 shares of the company’s stock valued at $4,529,000 after purchasing an additional 3,500 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Profound Medical in the 3rd quarter valued at $612,000. Institutional investors and hedge funds own 47.86% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.